Rémi Rosière hold a master’s degree in pharmaceutical and biomedical sciences (Université libre de Bruxelles (ULB) 2010) and obtained a PhD degree (ULB, 2016) for research completed at the Unit of Pharmaceutics and Biopharmaceutics, where he still has a position of lecturer. He has been the lead researcher in charge of the Inhatarget spin-off project since 2015. This project led to the launch of the pharma start-up InhaTarget Therapeutics that he co-founded in 2019. Remi is the current CSO of InhaTarget Therapeutics and responsible for all R&D aspects of the company, including:
- R&D management (proprietary products and research collaboration contracts)
- Innovation strategy
- Scientific partnership (pharmaceutical companies, universities, academic labs)
- Scientific communication
Remi specializes in drug formulations for inhalation, especially dry powders (e.g. advanced drug delivery systems, controlled-release formulations, carrier-based and carrier-free formulations, particle engineering, nanomedicine) and non-clinical development (analytical development, in vitro and in vivo studies, animal models). He has published about 20 peer-reviewed papers in internationally recognized journals, about 10 abstracts and conference proceedings. He is involved in 6 patent family applications.
